Maureen Farrell
Posts
Warring Billionaires, a Rogue Trader, a Divorce: One Hedge Fund’s Tale of Woe
Two Sigma, the $60 billion quantitative trading firm, has been beset by troubles this year that have tarnished its image and could hurt its future.
Davis Polk Rescinded Job Offers for Columbia and Harvard Students, but It May Reverse Itself
Davis Polk said the potential hires were leaders of student groups that had issued statements condemning Israel. But it also said it was reconsidering because...
A ‘Shadow’ Lending Market in the U.S., Funded by Insurance Premiums
Apollo was the first to use annuities to build a major financing business. Others followed, driving the growth of the private lending market and worrying...
How Short Seller Nathan Anderson Beat Carl Icahn “at His Own Game”
After a short seller targeted Icahn Enterprises, the activist investor made changes. At 87, he insists he’s not going anywhere and will refocus on rattling...
Shares of Carl Icahn’s Firm Tank After Dividend Is Cut
Bowing to pressure from a short seller, Mr. Icahn halved his company’s quarterly dividend and said he would return to the style of investing that...
Larry Fink’s Bet on Saudi Oil Money Is Also His Latest E.S.G. Woe
Mr. Fink finds himself on the back foot once again, with BlackRock appointing the head of Saudi oil giant Aramco to its board. Analysts say...
Fox News Settles Defamation Case With Venezuelan Businessman
In a letter to a New York judge, the parties said they had reached a settlement in a case related to claims of voter fraud...
How Silicon Valley Bank Sparked Global Financial Panic
While its C.E.O. extolled innovation and the future of tech, Silicon Valley Bank paid less attention to risk management and was caught flat-footed by economic...
Carlyle Names Harvey Schwartz, Former Goldman Sachs Executive, as CEO
Harvey Schwartz, who was passed over for the top job at Goldman Sachs, is taking over at the private equity giant.
Start-Up Raises $200 Million to Speed Up Drug Trials
New York-based Paradigm has raised a significant amount to simplify clinical trials. Its goal is ambitious, but its challenges are many, researchers say.